Ivan D. Horak

Head of Global Research and Development, Chief Scientific and Medical Officer at Symphogen Inc

Pederstrupvej 93, Ballerup, Region Hovedstaden, Denmark
Symphogen Inc
HQ Phone:
+45 45 26 50 50
Wrong Ivan Horak?

Last Updated 10/19/2017

General Information

Employment History

President for Research and Development, Chief Scientitifc Officer  - Enzon Pharmaceuticals , Inc.

CSO and Chief Marketing Officer  - The Global Leaders

Cso  - Immunomedics , Inc.

Vice President for Clinical Oncology  - Pharmacia Corporation

National Cancer Institute


M.D. degree  - University of Komenius


Member, Editorial Board  - Cancer Research

Member  - American Society of Clinical Oncology

Fellow  - American College of Physicians Inc

Member  - American Society of Hematology

Board Member  - Editorial

Member of Advisory Board  - Biotechnology Industry Organization

Member of Advisory Board  - All Conferences

Delegate  - GDS International Ltd

Member  - American Association for Cancer Research Inc

Member, Various Committees  - International Union

Web References  

Executive Management - symphogen

Ivan D. Horak, MD, FACP
Head of Global R&D, Chief Scientific and Medical Officer Prior to joining Symphogen in 2011, Dr. Horak served as President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals Inc. Before that, Dr. Horak served as Chief Scientific Officer of Immunomedics, responsible for development of novel antibodies. Dr. Horak has authored over 80 peer-reviewed publications and several book chapters within the fields of hematol- ogy, oncology, and immunology and has served on the editorial boards of several scientific journals. Dr. Horak is a board-certified oncologist. He is a Fellow of the American College of Physicians and a member of the American Association for Cancer Research (AACR), the American Society of Hematology (ASH), and the American Society Clinical Oncology (ASCO).

Read More
Archive - symphogen

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the addition of a new Chief Scientific/Medical Officer, Ivan D. Horak, M.D.,FACP and a new Chief Business Officer, Gayle M Mills.

Read More

Browse ZoomInfo’s Directories